PMID- 37652513
OWN - NLM
STAT- MEDLINE
DCOM- 20231102
LR  - 20231102
IS  - 1791-7549 (Electronic)
IS  - 0258-851X (Print)
IS  - 0258-851X (Linking)
VI  - 37
IP  - 5
DP  - 2023 Sep-Oct
TI  - Pembrolizumab Monotherapy Versus Pembrolizumab Plus Chemotherapy in Patients With 
      Head and Neck Squamous Cell Carcinoma.
PG  - 2188-2196
LID - 10.21873/invivo.13318 [doi]
AB  - BACKGROUND/AIM: Pembrolizumab monotherapy and pembrolizumab with chemotherapy 
      (combination therapy) are standard treatments for recurrent and metastatic head 
      and neck squamous cell carcinoma (R/M-HNSCC). This study aimed to explore which 
      of the two, pembrolizumab monotherapy or combination therapy is superior for 
      long-term use. PATIENTS AND METHODS: Participants of the study were 139 patients 
      with histologically confirmed squamous cell carcinoma who had been treated with 
      pembrolizumab monotherapy or combination therapy at the Kyushu University and 
      related facilities. We analysed differences regarding long-term survival rate and 
      adverse events (AEs) between the pembrolizumab monotherapy and combination 
      therapy groups. RESULTS: The overall 2-year progression-free survival and 2-year 
      overall survival were 28.6% and 41.8%, respectively; these results were not 
      significantly different between the two groups. Patients in the monotherapy group 
      with AEs had a significantly better prognosis than those without AEs (in both the 
      monotherapy and combination therapy groups). In the combination therapy group, 
      there was no difference in prognosis between those with AEs and those without AEs 
      (p=0.636). CONCLUSION: Considering the treatment of R/M-HNSCC from a long-term 
      perspective, we identified that it is better to use pembrolizumab as monotherapy 
      than to use it in combination with chemotherapy. Combination therapy did not 
      improve prognosis; moreover, it can also cause additional adverse effects.
CI  - Copyright (c) 2023, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Matsuo, Mioko
AU  - Matsuo M
AD  - Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan; matsuo.mioko.202@m.kyushu-u.ac.jp.
FAU - Masuda, Muneyuki
AU  - Masuda M
AD  - Department of Head and Neck Surgery, National Hospital Organization Kyushu Cancer 
      Center, Fukuoka, Japan.
FAU - Yamauchi, Moriyasu
AU  - Yamauchi M
AD  - Department of Otolaryngology, Head & Neck Surgery, Saga University Faculty of 
      Medicine, Saga, Japan.
FAU - Taura, Masahiko
AU  - Taura M
AD  - Department of Otolaryngology Fukuoka University School of Medicine, Fukuoka, 
      Japan.
FAU - Hashimoto, Kazuki
AU  - Hashimoto K
AD  - Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
FAU - Kogo, Ryunosuke
AU  - Kogo R
AD  - Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
FAU - Jiromaru, Rina
AU  - Jiromaru R
AD  - Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
FAU - Hongo, Takahiro
AU  - Hongo T
AD  - Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
FAU - Manako, Tomomi
AU  - Manako T
AD  - Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
FAU - Nakagawa, Takashi
AU  - Nakagawa T
AD  - Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - In Vivo
JT  - In vivo (Athens, Greece)
JID - 8806809
RN  - DPT0O3T46P (pembrolizumab)
SB  - IM
MH  - Humans
MH  - Squamous Cell Carcinoma of Head and Neck/drug therapy
MH  - Neoplasm Recurrence, Local/pathology
MH  - *Head and Neck Neoplasms/drug therapy
MH  - *Carcinoma, Squamous Cell/pathology
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
PMC - PMC10500496
OTO - NOTNLM
OT  - Chemotherapy
OT  - R/M-HNSCC
OT  - combination therapy
OT  - long-term prognosis
OT  - pembrolizumab
OT  - pembrolizumab monotherapy
OT  - recurrent and metastatic head and neck squamous cell carcinoma
COIS- The Authors declare that there are no conflicts of interest.
EDAT- 2023/09/01 00:41
MHDA- 2023/09/01 00:42
PMCR- 2023/09/03
CRDT- 2023/08/31 20:37
PHST- 2023/05/08 00:00 [received]
PHST- 2023/05/28 00:00 [revised]
PHST- 2023/06/19 00:00 [accepted]
PHST- 2023/09/01 00:42 [medline]
PHST- 2023/09/01 00:41 [pubmed]
PHST- 2023/08/31 20:37 [entrez]
PHST- 2023/09/03 00:00 [pmc-release]
AID - 37/5/2188 [pii]
AID - 10.21873/invivo.13318 [doi]
PST - ppublish
SO  - In Vivo. 2023 Sep-Oct;37(5):2188-2196. doi: 10.21873/invivo.13318.